Format

Send to

Choose Destination
Nat Methods. 2018 Nov;15(11):941-946. doi: 10.1038/s41592-018-0149-1. Epub 2018 Oct 8.

Guide Swap enables genome-scale pooled CRISPR-Cas9 screening in human primary cells.

Author information

1
Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA.
2
Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
3
Celgene, San Diego, CA, USA.
4
Merck, Cambridge, MA, USA.
5
Magenta Therapeutics, Cambridge, MA, USA.
6
Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA. jsnead@gnf.org.

Abstract

CRISPR-Cas9 screening allows genome-wide interrogation of gene function. Currently, to achieve the high and uniform Cas9 expression desirable for screening, one needs to engineer stable and clonal Cas9-expressing cells-an approach that is not applicable in human primary cells. Guide Swap permits genome-scale pooled CRISPR-Cas9 screening in human primary cells by exploiting the unexpected finding that editing by lentivirally delivered, targeted guide RNAs (gRNAs) occurs efficiently when Cas9 is introduced in complex with nontargeting gRNA. We validated Guide Swap in depletion and enrichment screens in CD4+ T cells. Next, we implemented Guide Swap in a model of ex vivo hematopoiesis, and identified known and previously unknown regulators of CD34+ hematopoietic stem and progenitor cell (HSPC) expansion. We anticipate that this platform will be broadly applicable to other challenging cell types, and thus will enable discovery in previously inaccessible but biologically relevant human primary cell systems.

PMID:
30297964
DOI:
10.1038/s41592-018-0149-1

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center